NASDAQ:HSTO - Histogen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.50
  • Forecasted Upside: 737.99 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.18
+0.30 (1.20%)

This chart shows the closing price for HSTO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Histogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSTO

Analyst Price Target is $1.50
▲ +737.99% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Histogen in the last 3 months. The average price target is $1.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 737.99% upside from the last price of $0.18.

This chart shows the closing price for HSTO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Histogen.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2022HC WainwrightLower Price TargetBuy$2.40 ➝ $1.50Low
8/30/2021HC WainwrightInitiated CoverageBuy$2.40High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/25/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Histogen logo
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.18
Low: $0.17
High: $0.19

50 Day Range

MA: $0.23
Low: $0.16
High: $0.42

52 Week Range

Now: $0.18
Low: $0.15
High: $1.23

Volume

505,478 shs

Average Volume

2,265,389 shs

Market Capitalization

$8.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Histogen?

The following equities research analysts have issued stock ratings on Histogen in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for HSTO.

What is the current price target for Histogen?

0 Wall Street analysts have set twelve-month price targets for Histogen in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 738.0%.
View the latest price targets for HSTO.

What is the current consensus analyst rating for Histogen?

Histogen currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HSTO will outperform the market and that investors should add to their positions of Histogen.
View the latest ratings for HSTO.

How do I contact Histogen's investor relations team?

Histogen's physical mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The company's listed phone number is (858) 526-3100 and its investor relations email address is [email protected] The official website for Histogen is www.histogen.com. Learn More about contacing Histogen investor relations.